Please login to the form below

Not currently logged in
Email:
Password:

Endo builds pain management business

Agrees $105m deal to acquire NuPathe
Endo Pharma

Endo Health Solutions is to acquire NuPathe and its migraine patch treatment in a deal that will see it pay $105m for the US-based pain specialist.

The move expands Endo's existing pain management business and brings NuPathe's lead product, the migraine treatment Zecuity, into the fold.

As part of the agreement, NuPathe is also eligible to receive additional cash payments if Endo meets sales targets for Zecuity, which is a single-use patch version of the painkiller sumatriptan – the active ingredient in GlaxoSmithKline's Imitrex.

NuPathe has previously announced its intention to seek a partnership to maximise the commercial potential of Zecuity, which became the first approved prescription migraine patch in the US at the beginning of the year.

As such, NuPathe has delayed launching Zecuity in the US, sating “the timing of the launch of Zecuity will be dependent upon the completion of a commercial partnership for Zecuity and/or obtaining the additional capital required for launch”.

They now have such a partner in Endo, which has experience in pain management via products such as Frova (frovatriptan succinate), Zydone (hydrocodone bitartrate/acetaminophen) and the Opana (oxymorphone hydrochloride) franchise of products.

Endo also has an existing pain patch in the form of Lidoderm, which contains the active ingredient lidocaine.

Rajiv De Silva, president and CEO of Endo, confirmed that the company intends to launch Zecuity in the first half of 2014.

The company will do this by “leveraging [its] existing commercial expertise in pain and migraine management and the current infrastructure of our branded pharmaceuticals business overall,” said De Silva.

NuPathe's CEO Armando Anido said: ”We believe this acquisition by Endo will increase the potential for Zecuity to make a meaningful difference for patients we have worked so hard to serve."

Article by
Thomas Meek

18th December 2013

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
#DemandDiversity: Black history in clinical trials: It's more than just Tuskegee [Infographic]
Take a look at this infographic showing some of the most notorious clinical trials and medical research in history....

Infographics